Studies2023-01-17T12:10:31+03:00
1February, 2023

HDM-FUN-Candidemia

By |February 1st, 2023|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia: The HDM-FUN-Candidemia trial Brief Description Invasive fungal infections are an important cause of morbidity and mortality and lead to numerous hospital and ICU admissions. Candidemia is associated with a suppressed immune status

10January, 2023

SAVE-LONG

By |January 10th, 2023|Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Symptom-guided Anakinra treatment for the Validation of immunE dysfunction persisting for LONG after hospital discharge for COVID-19 (SAVE-LONG) Brief Description SAVE-LONG is a call to the development of diagnostic tools and therapeutic modalities for patients with Long-COVID Syndrome. Details Status: ongoing Study Type: Non-interventional Study phase: II &

10October, 2022

INSPIRE

By |October 10th, 2022|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

1April, 2022

H4COVID

By |April 1st, 2022|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Hydrogen Sulfate guided therapy with STS for COVID-19 patients in need of Critical Care: The H4COVID open-label, randomized, triple-arm trial Brief Description H4COVID open-label study is aiming to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. Details Status: Recruiting

1April, 2022

BEYOND

By |April 1st, 2022|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title Bezlotoxumab Υielded Οutcomes by addressing personalized Needs in Clostridioides Difficile infection: the BEYOND double-blind randomized clinical trial Brief Description Previous data from our group have shown that integrated information from SNPs of the host DNA, IL-8 and the enrichment of the stool microbiome can indicate the patients with infection

1July, 2021

ImmunoSep

By |July 1st, 2021|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

ImmunoSep: The Hellenic Institute for the Study of Sepsis Announces the Successful Evaluation of the ImmunoSep Project by the European Commission Ongoing study Official Study Title Personalized Immunotherapy in Sepsis: a multicentre and multinational, double-blind, double-dummy randomized clinical trial Brief Description Previous findings coming from the randomized clinical trial PROVIDE have showed

Go to Top